Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2013-01-07 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec to present at J.P. Morgan Healthcare Conference
Regulatory Filings Classification · 100% confidence The document is a short press release dated January 7, 2013, announcing that Evotec AG's management will present at the J.P. Morgan Healthcare Conference on January 10, 2013. It provides details about the event (date, venue, presenter) and mentions that the presentation PDF will be provided online. Since this is an announcement about an upcoming presentation/event rather than the presentation itself, and it doesn't fit into specific financial reporting categories (like 10-K, ER, IR), it is best classified as a general Regulatory Filing or announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general corporate news that isn't a specific financial report or management change, although 'Investor Presentation' (IP) might seem close, this document is the *announcement* of the presentation, not the presentation material itself. Following Rule 2 (Menu vs Meal), this is an announcement, making RNS or RPA likely. Since it's a general corporate news item distributed via DGAP, RNS is the best fit as a miscellaneous regulatory announcement.
2013-01-07 English
Evotec expands collaboration with MedImmune, receives milestone payment
Regulatory Filings Classification · 100% confidence The document is a press release dated January 7, 2013, announcing that Evotec AG expanded its collaboration with MedImmune (AstraZeneca's biologics arm) after hitting a key milestone and receiving a payment of EUR0.5m. It details the expansion of the diabetes collaboration and mentions upfront payments, potential future milestones, and royalties. This type of announcement, which details a specific business development, partnership milestone achievement, or financial event outside of standard periodic reporting (like 10-K or IR), is typically classified as a general corporate announcement. Since it is not a formal Earnings Release (ER), a Capital/Financing Update (CAP), or a Director's Dealing (DIRS), and it is a specific corporate news item disseminated via DGAP, the most appropriate general category for non-standard corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements, or potentially a specific partnership/alliance announcement if one existed. Given the provided definitions, this is a specific corporate news item about an alliance milestone payment. It is not a formal financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific business development update. In the absence of a specific 'Partnership Update' code, RNS (Regulatory Filings/General Regulatory Announcements) is the best fit for a press release detailing a specific business transaction/milestone payment.
2013-01-07 English
Evotec acquires Cell Culture Service GmbH
M&A Activity Classification · 99% confidence The document is a press release dated January 3, 2013, announcing that Evotec AG has acquired all shares in Cell Culture Service GmbH (CCS). The text explicitly uses keywords like "acquisition," "Mergers & Acquisitions," and details the transaction structure (purchase price, earn-out). This clearly falls under the category of corporate actions related to M&A activity. The filing type code corresponding to Merger & Acquisition Activity is TAR.
2013-01-03 English
Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy
M&A Activity Classification · 99% confidence The document is a press release dated January 2, 2013, announcing a research collaboration between Evotec AG and Apeiron Biologics regarding cancer immunotherapy. It details the scope of the collaboration, includes quotes from management, and provides boilerplate information about both companies. This type of announcement, detailing a strategic partnership or alliance, does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or shareholder actions (DIV, DVA). It is a corporate news item about business development. Since there is no specific category for 'Strategic Alliance Announcement,' and it is not a general regulatory filing (RNS) or a presentation (IP), the closest fit among the provided options that covers general corporate news that isn't strictly financial reporting or management change is often categorized under Regulatory Filings (RNS) as a general announcement, or sometimes, if it implies future financing or structural change, it might lean towards CAP or TAR, but this is purely operational/research. Given the options, RNS is the most appropriate fallback for a general corporate news release that doesn't fit a more specific operational or financial category. However, since this is a clear announcement of a business development/alliance, and RNS is the general regulatory fallback, I will use RNS.
2013-01-02 English
Evotec AG: Release according to Article 26a, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It states the total number of voting rights as of a specific date (31 December 2012). This type of announcement, detailing the total number of shares with voting rights, is a specific regulatory disclosure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for a formal announcement regarding the total voting rights count, even though it is not the result of a specific vote, but rather the current total share structure impacting voting power. It is a regulatory filing, but DVA is more specific than RNS.
2012-12-31 English
Declaration of Compliance 2012
Governance Information Classification · 98% confidence The document is explicitly titled 'Declaration on the German Corporate Governance Code for the Year 2012'. It details compliance, or exceptions to compliance, with the recommendations of the German Corporate Governance Code (the 'Code') for the fiscal year 2012, as declared by the Management Board and Supervisory Board in accordance with Section 161 of the German Stock Corporation Act (AktG). This content directly relates to the company's internal rules, board structure, and governance practices, making it a Governance Information document.
2012-12-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.